Michelle Mitchell – CEO, Multiple Sclerosis Society, UK
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Address: No. 2, 32 Caxton Road,
Shepherd’s Bush, London W12 8AJ,United Kingdom
Tel: +44 (0)20 ‐ 7229 4552
Web: http://www.dwlanguages.com/page.asp?node=2
DWL is a specialist translation service provider for the pharmaceutical industry providing Medical Translation into all European Union (EU) and European Economic Area (EEA) languages and many others – mainly “from” and “into” English
Established in 1962, our business has grown through dedication and commitment to quality and service. This is acknowledged by our many long-standing clients and is perhaps most clearly demonstrated by their recommendation of DWL to others.
By recognising the specific needs of this market, DWL delivers a quality Medical Translation Service due to its expertise in selecting the most suitable linguists in combination with reliable project management and quality control. We understand the need to be flexible and responsive in our service, and that accuracy and thoroughness remain essential – even within the tightest of project timelines.
DW Languages provides translation solutions for the following areas:
Medical translation services
Pharmaceutical translation
Regulatory affairs
Clinical trials
Medical research and manufacturing
Legal documentation
Medical publishing and marketing communications
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Mike Belton of the British Swiss Chamber of Commerce discusses the capabilities of the organization, its role within the British and Swiss investment ecosystem, and how Switzerland can act as…
John Smith, chief executive of the PAGB, the UK’s consumer healthcare industry association, discusses the potential impacts of Brexit on the PAGB’s members, the importance of consumer healthcare to the…
Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why…
In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his…
Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may…
British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of…
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on…
Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia…
See our Cookie Privacy Policy Here
